Target Name: MKNK2
NCBI ID: G2872
Review Report on MKNK2 Target / Biomarker Content of Review Report on MKNK2 Target / Biomarker
MKNK2
Other Name(s): GPRK7 | MKN2 | MAPK signal-integrating kinase 2 | MNK2 | MAP kinase-interacting serine/threonine-protein kinase 2 | MAPK interacting serine/threonine kinase 2, transcript variant 2 | MAPK interacting serine/threonine kinase 2, transcript variant 1 | Mnk2 | MAPK interacting serine/threonine kinase 2 | MKNK2_HUMAN | MAP kinase signal-integrating kinase 2 | MKNK2 variant 2 | MAP kinase-interacting serine/threonine-protein kinase 2 (isoform 2) | MKNK2 variant 1 | G protein-coupled receptor kinase 7 | MAP kinase interacting serine/threonine kinase 2 | MAP kinase-interacting serine/threonine-protein kinase 2 (isoform 1)

MKNK2 Gene: Potential Drug Target Or Biomarker for Cancer

MKNK2 (GPRK7), also known as NKG2, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The gene is located on chromosome 1p36 and has been shown to be involved in the regulation of neural development, plasticity, and survival.

The MKNK2 gene was first identified in 2007 as a potential gene that could be involved in the development of cancer. This was based on the fact that the gene was highly expressed in many cancer types, including breast, ovarian, and prostate cancers. Additionally, the gene was shown to be involved in the regulation of cell division, which is a key factor in the development of cancer.

Since then, more research has been conducted on the MKNK2 gene, and it has been shown to be involved in a number of different processes in the body, including:

1. Cell Communication: The MKNK2 gene is involved in the regulation of cell-cell communication, which is critical for the development and maintenance of tissues and organs.
2. Neural Development and Plasticity: The MKNK2 gene is involved in the regulation of neural development and plasticity, which are critical for the formation and function of the nervous system.
3. Cell Survival: The MKNK2 gene is involved in the regulation of cell survival, which is critical for the development and maintenance of tissues and organs.
4. inflammation: The MKNK2 gene is involved in the regulation of inflammation, which can contribute to the development and progression of a number of diseases, including cancer.

As a result of these findings, the MKNK2 gene has been identified as a potential drug target or biomarker for a number of diseases, including cancer. Researchers are currently working to develop drugs that can target the MKNK2 gene and are investigating the potential benefits and risks of these treatments.

One of the main challenges in developing drugs that target the MKNK2 gene is the fact that it is involved in a number of different processes in the body. This makes it difficult to predict how a drug will interact with the gene and whether it will be effective. Additionally, the fact that the MKNK2 gene is involved in the regulation of many different processes in the body makes it difficult to understand how a drug will work in different tissues and organs.

Despite these challenges, researchers are making progress in the development of drugs that target the MKNK2 gene. For example, a team of researchers at the University of California, San Francisco has developed a drug that targets the MKNK2 gene and is currently being tested in clinical trials for the treatment of cancer.

In addition, researchers are also investigating the potential benefits and risks of drugs that target the MKNK2 gene. For example, some studies have suggested that these drugs may be effective in treating certain types of cancer, while others have suggested that they may be ineffective or even harmful.

Overall, the MKNK2 gene is a promising target for the development of drugs that can treat a wide range of diseases, including cancer. Further research is needed to fully understand the role of this gene in the development and progression of these diseases and to develop safe and effective drugs that can target it.

Protein Name: MAPK Interacting Serine/threonine Kinase 2

Functions: Serine/threonine-protein kinase that phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. May play a role in the response to environmental stress and cytokines. Appears to regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. Required for mediating PP2A-inhibition-induced EIF4E phosphorylation. Triggers EIF4E shuttling from cytoplasm to nucleus. Isoform 1 displays a high basal kinase activity, but isoform 2 exhibits a very low kinase activity. Acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis. Negative regulator for signals that control generation of arsenic trioxide As(2)O(3)-dependent apoptosis and anti-leukemic responses. Involved in anti-apoptotic signaling in response to serum withdrawal

The "MKNK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKNK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1